Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Exploratory Study of Erlotinib and SNDX-275 in Patients With Non-small Cell Lung Carcinoma Who Are Progressing on Erlotinib

NCT00750698 is registered in ClinicalTrials.gov with Syndax Pharmaceuticals as lead sponsor.

NCT NCT00750698
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00750698 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Exploratory Study of Erlotinib and SNDX-275 in Patients With Non-small Cell Lung Carcinoma Who Are Progressing on Erlotinib
Lead sponsor
Syndax Pharmaceuticals
Phase
Phase 2
Overall status
Terminated
Start date
August 31, 2008
Completion date
June 30, 2010
Enrollment
8 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

non small cell lung cancer